We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

New Rapid Lateral Flow Antigen COVID-19 Testing Platform Processes 200-300 People Each Hour and Reports Results in 15 Minutes

By LabMedica International staff writers
Posted on 20 Oct 2020
Print article
Illustration
Illustration
A new rapid lateral flow antigen COVID-19 testing platform gives testers the ability to process an unprecedented 200-300 people each hour and report results within 15 minutes utilizing testing kits from Quidel, BD and Abbott.

The COVID CleanPass system from Apollo Medco (Atlanta, GA, USA) is a mobile app-linked, HIPAA compliant, cloud secure and data-backed COVID-19 testing platform. Straight forward and effortless to operate, its built-in software walks anyone through all and every step of testing. Its trouble-free transportability and total weight of less than 20 pounds makes any location perfect for use. Its bulletproof and waterproof case floats and protects all electronics inside, no matter how harsh the environment. In case of power failure, its eight-hour battery or solar powered panels ensure that testing continues.

Hassle-free, simple to operate, and compatible with worldwide power sources, the COVID CleanPass is a reliable system that is enabling businesses across the globe to reopen and start growing with absolute peace of mind. With its compact form and overhead airline compliance, immediate global deployment to the next viral outbreak is actually possible. Currently, Apollo Medco is beta testing its COVID-19 testing platform and applying for Emergency Use Authorization from the US Food and Drug Administration which is expected in November 2020. Distribution of the new COVID CleanPass system is then expected to begin in late November 2020.

"Our new COVID CleanPass platform is the most advanced, quality-assured, rapid testing platform in the world," said Apollo Medco President & CEO Ken Dunwody. "We've supercharged the overall COVID testing process by delivering fast and accurate results to the patient in an efficient manner. The front-end of our platform includes our Apollo 'Mission Control' diagnostic unit while the back-end of our platform includes our mobile app-linked, cloud secure, HIPAA compliant test reporting system which includes a dynamic Web portal that maps, tracks and reports COVID hot zones in real time."

"Each Apollo Medco testing system is contained in a portable rugged case and includes a battery that lasts 10 hours, iPad with the proprietary mobile app system, time tracking system, printer and a universal lateral flow analysis device. All testing companies will have access to our HIPPA compliant Web portal for accepting new testing requests, scheduling, assigning systems to testers and managing testing assignments. Automatic reporting of all COVID-19 tests through the Apollo Medco COVID CleanPass system will enable testing companies to provide quick, accurate information," added Dunwody.

Related Links:
Apollo Medco

Gold Member
COVID-19 TEST READER
COVID-19-CHECK-1 EASY READER+
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Silver Member
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Silver Member
Total Hemoglobin Monitoring System
GREENCARE Hb

Print article

Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Sekisui Diagnostics UK Ltd.